从IMpower133看PDL1抑制剂如何改变小细胞肺癌治疗格局(一) 1815年医学家们便开始独立研究肺癌,但直到1926年英国医生Barnard发表论著,大家才认识到纵隔的神秘燕麦细胞“肉瘤”本质上是一种肺癌——又称小细胞肺癌(Small cell lung cancer, SCLC)。...
从IMpower133看PDL1抑制剂如何改变小细胞肺癌治疗格局(一) 1815年医学家们便开始独立研究肺癌,但直到1926年英国医生Barnard发表论著,大家才认识到纵隔的神秘燕麦细胞“肉瘤”本质上是一种肺癌——又称小细胞肺癌(Small cell lung cancer, SCLC)。又过了30多年,退伍军人管理局肺研究组(Veterans Administration Lung Stu...
1815年医学家们便开始独立研究肺癌,但直到1926年英国医生Barnard发表论著,大家才认识到纵隔的神秘燕麦细胞“肉瘤”本质上是一种肺癌——又称小细胞肺癌(Small cell lung cancer, SCLC)。又过了30多年,退伍军人管理局肺研究组(Veterans Administration Lung Study Group)提出可以将SCLC分成局限期(LS)和广泛期(ES)——...
Squamous Non-Small-Cell Lung Cancer (IMpower131): Results From a Randomized
本案例中用5mg泼尼松龙控制住了病情,给我们展示了长期低剂量激素维持的情况下,免疫药物也能发挥很好的治疗效果。 参考文献: Takahiro Taki et al. Successful Treatment of Non-small-cell Lung Cancer with Atezolizumab following Tubulointerstitial Nephritis due to Pembrolizumab.2020...
Singh N, Seetharamu N. Complete response with anti-PD-L1 antibody following progression on anti-PD-1 antibody in advanced non-small cell lung cancer. BMJ Case Rep. 2020;13(8):e236101. Published 2020 Aug 24. doi:10.1136/bcr-2020-236101...
5. Reck M, CIuleanu TE, Cobo M, et al. First-line nivolumab (NIVO) plus ipilimumab (IPI) plus two cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients with advanced non-small cell lung cancer (NSCLC): Two-year update from CheckMate 9LA. J Clin Oncol. 2021;39...
[8]. Pembrolizumabplus allogeneic NK cells in advanced non-small cell lung cancer patients. JClin Invest. 2020 Apr 13. pii: 132712.
5. Reck M, CIuleanu TE, Cobo M, et al. First-line nivolumab (NIVO) plus ipilimumab (IPI) plus two cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients with advanced non-small cell lung cancer (NSCLC): Two...
欢迎关注癌度,我们陪您走好防癌抗癌的每一步! . 参考文献: Nikolic Nikola , et al., Brief Report: Predictive value of PD-L1 expression in non-small-cell lung can- cer - should we set the bar higher for monotherapy?, Clinical Lung Cancer (2023)...